By SNEHA KABARIA
A team of Cornell chemical engineers in partnership with New England Biolabs have developed a method to efficiently produce antibodies in the cytoplasm in E. coli bacteria, leading to a new drug development platform. The research was led by co-senior author Prof. Matthew DeLisa, chemical engineering, and first author Michael-Paul Robinson ’16 grad. Robinson is part of the Cornell Sloan and Colman Fellowship Program, which supplied funding for the project. The research, which has been ongoing for approximately five years, was published in a paper entitled “Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria” in Nature Communications on Aug. 17.